Compounders Research Compare

Candel Therapeutics, Inc.(CADL)

Biotechnology · Needham, MA

$9.87-0.36 (-3.52%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.

Needham, MA

55 employees

www.candeltx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Paul-Peter Tak

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T20:30:52.800Z.

Stored calculation inputs

Calculation as of: 2026-10-06T20:30:52.800Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 723,176,874
Total debt · period ending 2026-06-30: 49,517,000
Cash · period ending 2026-06-30: 201,565,000
TTM operating income · period ending 2026-06-30: -71,989,000

FMP input reference: 370e13d786cc28e63fbc6719e554b7ac483294971c86eef7c80c09e39811c756

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CADL EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

CADL Competitors' EV/EBIT Ratio

Candel Therapeutics, Inc.

Current

Market Cap

$723.18M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Achieve Life Sciences, Inc.

Market Cap

$721.69M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Avalo Therapeutics, Inc.

Market Cap

$714.37M

EV/EBIT Ratio

N/A

TTM Avg

877.08x

3Y Avg

871.89x

5Y Avg

871.89x

Collegium Pharmaceutical, Inc.

Market Cap

$709.65M

EV/EBIT Ratio

9.07x

TTM Avg

12.78x

3Y Avg

12.26x

5Y Avg

15.40x

Apnimed, Inc.

Market Cap

$742.70M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ArriVent BioPharma, Inc.

Market Cap

$702.82M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Design Therapeutics, Inc.

Market Cap

$747.61M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cytek Biosciences, Inc.

Market Cap

$694.79M

EV/EBIT Ratio

N/A

TTM Avg

501.20x

3Y Avg

422.57x

5Y Avg

422.57x

Wave Life Sciences Ltd.

Market Cap

$693.61M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Attovia Therapeutics, Inc.

Market Cap

$753.02M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Candel Therapeutics, Inc. (CADL)	$723.18M	N/A	N/A	N/A	N/A
Achieve Life Sciences, Inc. (ACHV)vs ›	$721.69M	N/A	N/A	N/A	N/A
Avalo Therapeutics, Inc. (AVTX)vs ›	$714.37M	N/A	877.08x	871.89x	871.89x
Collegium Pharmaceutical, Inc. (COLL)vs ›	$709.65M	9.07x	12.78x	12.26x	15.40x
Apnimed, Inc. (APMD)vs ›	$742.70M	N/A	N/A	N/A	N/A
ArriVent BioPharma, Inc. (AVBP)vs ›	$702.82M	N/A	N/A	N/A	N/A
Design Therapeutics, Inc. (DSGN)vs ›	$747.61M	N/A	N/A	N/A	N/A
Cytek Biosciences, Inc. (CTKB)vs ›	$694.79M	N/A	501.20x	422.57x	422.57x
Wave Life Sciences Ltd. (WVE)vs ›	$693.61M	N/A	N/A	N/A	N/A
Attovia Therapeutics, Inc. (ATTO)vs ›	$753.02M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics